Cerebrospinal Fluid Biomarkers in Alzheimer's Disease, Vascular Dementia and Ischemic Stroke Patients: a Critical Analysis

Overview

Journal J Neurol

Specialty Neurology

Date 2013 Jul 24

PMID 23877436

Citations 35

Authors

Lisa Kaerst

Andre Kuhlmann

Dirk Wedekind

Katharina Stoeck

Peter Lange

Inga Zerr

Affiliations

Soon will be listed here.

Abstract

Vascular factors are thought to contribute to the development of disease pathology in neurodegenerative dementia such as Alzheimer's disease (AD). Another entity, called vascular dementia (VaD), comprises a less defined group of dementia patients having various vascular diseases that especially emerge in the elderly population and require valid options for examination and differential diagnosis. In the context of a retrospective study, we analyzed the cerebrospinal fluid (CSF) biomarkers t-tau, p-tau and Aß42 of a total of 131 patients with AD (n = 47), mild cognitive impairment (MCI) (n = 22), VaD (n = 44) and stroke (n = 18). We found a remarkable alteration in CSF biomarker profile in AD, VaD and in acute ischemic events. CSF profile in AD patients was altered in a very similar way as in stroke patients, without statistical differences. In stroke, increase depend largely on size and duration after the initial event. Total tau levels were useful to differ between VaD and stroke. Aß42 decreased in a similar way in AD, VaD and stroke and had a trend to lower levels in MCI but not in controls.

Citing Articles

The Blood-Cerebrospinal Fluid Barrier Dysfunction in Brain Disorders and Stroke: Why, How, What For?.

Mathias K, Machado R, Cardoso T, Tiscoski A, Piacentini N, Prophiro J Neuromolecular Med. 2024; 26(1):38.

PMID: 39278883 DOI: 10.1007/s12017-024-08806-0.

Body fluid multiomics in 3PM-guided ischemic stroke management: health risk assessment, targeted protection against health-to-disease transition, and cost-effective personalized approach are envisaged.

Chen R, Wang X, Li N, Golubnitschaja O, Zhan X EPMA J. 2024; 15(3):415-452.

PMID: 39239108 PMC: 11371995. DOI: 10.1007/s13167-024-00376-2.

Association of oxidative stress and inflammatory metabolites with Alzheimer's disease cerebrospinal fluid biomarkers in mild cognitive impairment.

Ahmad S, Yang W, Orellana A, Frolich L, de Rojas I, Cano A Alzheimers Res Ther. 2024; 16(1):171.

PMID: 39080778 PMC: 11287840. DOI: 10.1186/s13195-024-01542-4.

Associations between cardiometabolic multimorbidity and cerebrospinal fluid biomarkers of Alzheimer's disease pathology in cognitively intact adults: the CABLE study.

Li Q, Hu H, Zhang G, Hu H, Ou Y, Huang L Alzheimers Res Ther. 2024; 16(1):28.

PMID: 38321520 PMC: 10848421. DOI: 10.1186/s13195-024-01396-w.

Cerebrospinal Fluid Biomarkers for Diagnosis and the Prognostication of Acute Ischemic Stroke: A Systematic Review.

Naik A, Adeleye O, Koester S, Winkler E, Hartke J, Karahalios K Int J Mol Sci. 2023; 24(13).

PMID: 37446092 PMC: 10341720. DOI: 10.3390/ijms241310902.

References

Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L . Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 2006; 5(3):228-34. DOI: 10.1016/S1474-4422(06)70355-6. View

Buchhave P, Minthon L, Zetterberg H, Wallin A, Blennow K, Hansson O . Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry. 2012; 69(1):98-106. DOI: 10.1001/archgenpsychiatry.2011.155. View

Zieren N, Duering M, Peters N, Reyes S, Jouvent E, Herve D . Education modifies the relation of vascular pathology to cognitive function: cognitive reserve in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Neurobiol Aging. 2012; 34(2):400-7. DOI: 10.1016/j.neurobiolaging.2012.04.019. View

Hesse C, Rosengren L, Vanmechelen E, Vanderstichele H, Jensen C, Davidsson P . Cerebrospinal fluid markers for Alzheimer's disease evaluated after acute ischemic stroke. J Alzheimers Dis. 2002; 2(3-4):199-206. DOI: 10.3233/jad-2000-23-402. View

Lanari A, Parnetti L . Cerebrospinal fluid biomarkers and prediction of conversion in patients with mild cognitive impairment: 4-year follow-up in a routine clinical setting. ScientificWorldJournal. 2009; 9:961-6. PMC: 5823093. DOI: 10.1100/tsw.2009.106. View

Ohrfelt A, Andreasson U, Simon A, Zetterberg H, Edman A, Potter W . Screening for new biomarkers for subcortical vascular dementia and Alzheimer's disease. Dement Geriatr Cogn Dis Extra. 2011; 1(1):31-42. PMC: 3199889. DOI: 10.1159/000323417. View

Pluta R, Jolkkonen J, Cuzzocrea S, Pedata F, Cechetto D, Popa-Wagner A . Cognitive impairment with vascular impairment and degeneration. Curr Neurovasc Res. 2011; 8(4):342-50. DOI: 10.2174/156720211798120981. View

Zheng G, Wang X, Wang Y, Wang X . Tau as a potential novel therapeutic target in ischemic stroke. J Cell Biochem. 2009; 109(1):26-9. DOI: 10.1002/jcb.22408. View

Hesse C, Rosengren L, Andreasen N, Davidsson P, Vanderstichele H, Vanmechelen E . Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. Neurosci Lett. 2001; 297(3):187-90. DOI: 10.1016/s0304-3940(00)01697-9. View

10.

Paraskevas G, Kapaki E, Papageorgiou S, Kalfakis N, Andreadou E, Zalonis I . CSF biomarker profile and diagnostic value in vascular dementia. Eur J Neurol. 2009; 16(2):205-11. DOI: 10.1111/j.1468-1331.2008.02387.x. View

11.

McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan E . Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984; 34(7):939-44. DOI: 10.1212/wnl.34.7.939. View

12.

Biagioni M, Galvin J . Using biomarkers to improve detection of Alzheimer's disease. Neurodegener Dis Manag. 2011; 1(2):127-139. PMC: 3209959. DOI: 10.2217/NMT.11.11. View

13.

Hertze J, Minthon L, Zetterberg H, Vanmechelen E, Blennow K, Hansson O . Evaluation of CSF biomarkers as predictors of Alzheimer's disease: a clinical follow-up study of 4.7 years. J Alzheimers Dis. 2011; 21(4):1119-28. DOI: 10.3233/jad-2010-100207. View

14.

Bitsch A, Horn C, Kemmling Y, Seipelt M, Hellenbrand U, Stiefel M . Serum tau protein level as a marker of axonal damage in acute ischemic stroke. Eur Neurol. 2002; 47(1):45-51. DOI: 10.1159/000047946. View

15.

Wunderlich M, Lins H, Skalej M, Wallesch C, Goertler M . Neuron-specific enolase and tau protein as neurobiochemical markers of neuronal damage are related to early clinical course and long-term outcome in acute ischemic stroke. Clin Neurol Neurosurg. 2006; 108(6):558-63. DOI: 10.1016/j.clineuro.2005.12.006. View

16.

Schmidtke K, Hermeneit S . High rate of conversion to Alzheimer's disease in a cohort of amnestic MCI patients. Int Psychogeriatr. 2007; 20(1):96-108. DOI: 10.1017/S1041610207005509. View

17.

Gorelick P, Scuteri A, Black S, DeCarli C, Greenberg S, Iadecola C . Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association. Stroke. 2011; 42(9):2672-713. PMC: 3778669. DOI: 10.1161/STR.0b013e3182299496. View

18.

Pluta R, Ulamek M, Jablonski M . Alzheimer's mechanisms in ischemic brain degeneration. Anat Rec (Hoboken). 2009; 292(12):1863-81. DOI: 10.1002/ar.21018. View

19.

Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M . CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA. 2009; 302(4):385-93. DOI: 10.1001/jama.2009.1064. View

20.

Thaweepoksomboon J, Senanarong V, Poungvarin N, Chakorn T, Siwasariyanon N, Washirutmangkur L . Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand. J Med Assoc Thai. 2011; 94 Suppl 1:S77-83. View